TNFRSF8 and lymphoma: Later, the CD30-specific antibody-drug conjugate, with a completely different mechanism of action, named Brentuximab Vedotin, offering very promising results, was approved by Food and Drug Administration (FDA) to be incorporated in the treatment of CD30+ lymphomas [15].